Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Telos CorporationNASDAQ: TLS
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 1083.2% from a year ago
Other non-current liabilities stood at $1.12M at the end of Q1 FY2026, up 1083.2% from a year earlier and down 12.4% from the prior quarter. Over 3 fiscal years it compounded at +62.9% a year.
Context
- Other non-current liabilities amounted to 0.8% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +1083.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.28M USD
- Year-over-year change
- +1309.9%
- 4-year CAGR
- +8.2%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.28M | +1309.9% |
| FY2024 | 2024-12-31 | 91K | +106.8% |
| FY2023 | 2023-12-31 | 44K | -85.2% |
| FY2022 | 2022-12-31 | 297K | -68.2% |
| FY2021 | 2021-12-31 | 935K | — |
Other Non-current Liabilities vs competitors
How TLS compares with its peers on the latest reported figures
- TLS's Mar 2026 other non-current liabilities of $1.12M is the 7th highest of the 10 companies compared; the peer median is $2.26M.
- Its year-over-year change of +1083.2% is the 2nd highest of 8, against a peer median of +50.9%.
- Other non-current liabilities amounts to 0.8% of total assets for TLS, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.89B | +30.9% | +7.9% | 19.1% | |
| Mar 2026 | $26.33M | +0.2% | -16.1% | 4.3% | |
| Mar 2026 | $4.23M | +50.9% | +12.1% | 1.4% | |
| Mar 2026 | $3.95M | +93.3% | -31.5% | 1.0% | |
| Mar 2026 | $2.26M | -0.7% | -41.5% | 0.0% | |
| Mar 2026 | $1.63M | +182.6% | — | 0.2% | |
| Mar 2026 | $1.12M | +1083.2% | +62.9% | 0.8% | |
| Mar 2026 | $102K | — | — | 0.1% | |
NBPNovaBridge Biosciences | Dec 2025 | $73.05K | +13948.5% | -94.2% | 0.2% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TLS) | $2.26M | +50.9% | -23.8% | 0.2% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 126.56M | 119.31M | 99.26M | 54.58M | 53.18M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 59.84M | 40.07M | 30.42M | 19.17M | 17.53M |
| Inventory | 1.25M | 2.88M | 1.42M | 1.78M | 996K |
| Other Current Assets | 732K | 893K | 1.37M | 793K | 12.14M |
| Total Current Assets | 191.71M | 167.96M | 139.99M | 91.42M | 94.41M |
| Property, Plant & Equipment (Net) | 15.99M | 12.96M | 10.29M | 10.3M | 7.88M |
| Goodwill | 17.92M | 17.92M | 17.92M | 17.92M | 3.01M |
| Intangible Assets | 19.2M | 37.42M | 39.62M | 30.41M | 30.28M |
| Long-term Investments | 0 | 133K | 136K | 3M | 3.89M |
| Tax Assets | 0 | 758K | 0 | 0 | 0 |
| Other Non-current Assets | 1.25M | 246K | 749K | 5.19M | 391K |
| Total Non-current Assets | 54.37M | 69.43M | 68.71M | 66.82M | 45.45M |
| Total Assets | 246.08M | 237.4M | 208.7M | 158.24M | 139.86M |
| Account Payables | 7.87M | 12.61M | 8.31M | 1.15M | 4.09M |
| Short-term Debt | 0 | 1.25M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.38M | 6.44M | 6.73M | 6.84M | 11.22M |
| Other Current Liabilities | 7.99M | 14.86M | 7.77M | 8.04M | 12.31M |
| Total Current Liabilities | 50.94M | 45.5M | 39.2M | 22.14M | 36.78M |
| Long-term Debt | 0 | 7.21M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 723K | 758K | 813K | 813K | 53K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 935K | 297K | 44K | 91K | 1.28M |
| Total Non-current Liabilities | 14.89M | 19.54M | 10.5M | 8.96M | 7.13M |
| Total Liabilities | 65.83M | 65.04M | 49.7M | 31.1M | 43.91M |
| Common Stock | 105K | 106K | 109K | 111K | 111K |
| Retained Earnings | (186.98M) | (240.41M) | (274.83M) | (327.35M) | (363.89M) |
| Accumulated OCI | (27K) | (55K) | (60K) | (129K) | (96K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 180.25M | 172.35M | 159M | 127.14M | 95.95M |
| Total Debt | 15.25M | 21.69M | 11.47M | 10.15M | 8.06M |
| Net Debt | (111.31M) | (97.62M) | (87.79M) | (44.43M) | (45.12M) |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.